Compare Ascendis Pharma A/S (ASND) vs Diageo plc (DEO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Diageo plc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Diageo plc trades at $81.81 (market cap $44.73B). The key difference: Diageo plc is far larger — about 2.5× Ascendis Pharma A/S's market cap, and Diageo plc pays a 4.05% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DEO | |
|---|---|---|
Market Cap | $17.74B | $44.73B |
Sector | Health | Technology |
52-Week High | $277.18 | $115.33 |
52-Week Low | $163.32 | $72.47 |
Enterprise Value | $18.11B | $65.55B |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Diageo (DEO) trades at $82.03, up 1.76% with bearish technical signals but mixed fundamentals. The stock shows strong profitability with 12.19% net margins and 22.29% ROE, though recent earnings were mixed with a Q2 2025 miss. Analyst sentiment leans positive with 49% buy ratings, but technical indicators show 15 sell signals versus 1 buy. Recent news highlights CEO Dave Lewis's upcoming strategy update amid US market challenges and promotional increases to stabilize sales.
The outlook remains cautious due to weak US demand and competitive pressures, but valuation at multi-year lows and cost-saving initiatives offer potential upside. Key risks include execution on the new strategy and consumer spending trends. Investors should weigh the dividend yield and recovery potential against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →
